Pre-implantation genetic diagnosis or PGD is a technique for analyzing embryos to differentiate those that are carriers of a genetic abnormality from those that are genetically normal.
The final objective of this technique is to avoid the birth of children with chromosomal abnormalities since embryos diagnosed as abnormal are discarded for transfer. This increases the probability of embryo implantation and therefore the probability of successful in vitro fertilization (IVF) treatment.
The different sections of this article have been assembled into the following table of contents.
PGD stands for preimplantation genetic diagnosis. This is a technique that makes it possible to eliminate the probability of transmission of genetic diseases from parents to children. PGD normally detects point mutations in embryos that cause serious genetic diseases.
Thanks to PGD, it is possible to select those normal embryos from a group in which the proportion of abnormal embryos with genetic alterations is suspected to be above normal. Therefore, it is extremely important to perform PGD in an IVF cycle before transferring the embryos into the mother's uterus.
The main reason for performing PGD is that the morphological selection of the embryos does not allow the discarding of embryos with chromosomal abnormalities, so an embryo can be classified as being of good quality and genetically abnormal.
It should be noted that PGD is not the same as a prenatal diagnosis since the latter is useful for detecting abnormalities during pregnancy.
Primarily, PGD technology is indicated as a complement to the IVF-ICSI process in the following situations:
It is necessary to know that the genetic diagnosis of the embryos implies the manipulation of these, which can be a risk. For this reason, it is important to assess the risk-benefit balance and perform the procedure only when it is necessary and can improve the chances of success.
PGD is a complementary technique to the IVF process (in vitro fertilization) Below are the steps to follow in order to perform PGD on the embryos before their transfer to the uterus:
The results obtained will indicate whether the embryo analyzed has a normal chromosomal endowment or if, on the contrary, it presents a genetic alteration that could lead to disease.
It needs to be remembered that, at this point, the embryo is at a very early stage of development and its cells are totipotent stem cells, i.e. they can differentiate into any type of cell in the human body until they form a complete organism. For this reason, the extraction of one or two cells from the embryo will not affect its further development.
Nor should it be forgotten that through this technique the genetic endowment of one or a few cells of the embryo is analyzed. Therefore, the reliability of the result, although close, is not 100%. One possibility is the development of what is known as mosaicism, a phenomenon in which some cells have different genetic information from others.
As we have highlighted before, the genetic analysis of embryos allows us to avoid the transfer of embryos with genetic abnormalities that could lead to children with serious diseases.
There are genetic alterations incompatible with life that, in the event of a transfer, would result in implantation failure or abortion. However, there are other abnormalities that can lead to the birth of children with developmental disorders. An example of the latter case is found in chromosomal syndromes such as Down syndrome (trisomy 21), Patau syndrome (trisomy 13), Edwards syndrome (trisomy 18), etc.
When people decide to do PGD when trying for pregnancy, they can achieve the following benefits:
Like any assisted reproduction technique, on the other side of the coin, we find the negative consequences of performing PGD. We’ll show some of them below:
New techniques of embryo manipulation and advances in reproductive medicine are making the effect on embryos less and less harmful. Yet it is still a risk.
United Kingdom and United States of America do not have the same vision about PGD process use.
European Commission's science and knowledge service in its report about Preimplantation Genetic Diagnosis in Europe says that:
The Since PGD involves creation, storage and use of embryos outside the body, it requires a licence from the Human Fertilisation and Embryology Authority (HFEA), the UK regulatory body for this area.
The HFEA receives its authority from the Human Fertilisation and Embryology Act of 1990 and Human Fertilisation and Embryology Bill of 2007.
PGD is authorized under the following situations:
Indeed, it can be used to select against severe medical conditions or to select a human leukocyte antigen (HLA) match for a sick relative.
On the contrary, in the USA, there are no federal or state laws that regulate the use of PGD. So, the use of PGD is left to doctors' discretion.
According to the Comparative preimplantation genetic diagnosis policy in Europe and the USA and its implications for reproductive tourism present on the website of US National Library of Medicine and National Institutes of Health:
The genetic testing process itself (i.e. the analytic quality of the tests and the qualifications of the technicians who carry them out) are subject to the Clinical Laboratory Improvement Amendments (CLIA).
Thus, in the United States, PGD can be performed for example in order to select the gender of the future baby, that is why this technique is seen as controversial.
The surrogacy process is usually performed by in vitro fertilization. For this reason, it is possible to carry out the analysis of the embryo's genes through PGD.
In fact, it is something that is usually done, especially in the United States, the preferred destination for surrogacy treatment. However, it is important for intended parents to know both the benefits and disadvantages of PGD when not responding to specific indications.
While it is true that we reduce the likelihood of miscarriage, as well as possible ethical complications, it may be that, as we have already said, the embryos are not capable of surviving the process and we cannot perform the transfer because viable embryos are not available.
PGD is recommended to identify embryos that are at risk for a single gene disorder, e.g. cystic fibroses, and for testing for chromosomal structural rearrangements, e.g. translocations, deletions/duplications. PGS or now called PGT, preimplantation genetic testing, is used to detect aneuploidy.
Yes, it is possible to freeze the embryos, thaw them and then do a biopsy to analyze them genetically. In any case, this is not usual. Generally, what is done is to leave the embryos in culture until the day of the biopsy, either on day 3 or day 5.
The protocol to follow will depend on each laboratory and the personal situation of the patients.
Performing PGD on embryos implies an increase in the cost of in vitro fertilization of between 3,000 and 4,000 euros approximately. Therefore, the total price of an IVF-DGP process is around 9,000 euros.
Yes, cystic fibrosis is one of the diseases susceptible to genetic analysis before implantation.
As we have mentioned, PGD involves the manipulation of embryos as an Assisted Reproductive Technology. If you want to learn more about the techniques performed in Assisted Reproduction, we recommend you to read the following post: Assisted Reproductive Technology (ART) – Techniques Used in Surrogacy.
Some of the most common diseases for which PGD is requested have also been included in the article. In this article you have more explanation about it: What Genetic Diseases Can PGD Test for?
We make a great effort to provide you with the highest quality information.
🙏 Please share this article if you liked it. 💜💜 You help us continue!
The European Commission's science and knowledge service about Preimplantation Genetic Diagnosis in Europe: [ici]
Comparative preimplantation genetic diagnosis policy in Europe and the USA and its implications for reproductive tourism by US National Library of Medicine and National Institutes of Health [ici]